Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Treatment of Myelofibrosis Using I.V. Treosulfan and Autologous Peripheral Blood Progenitor Cell Transplantation Is Feasible and Results in Hematologic Responses – Long-Term Follow-up and Final Analysis of a One-Armed Clinical Study and of Individual Cases

Eike C. Buss, MD, Julian Topaly, MD, Hans H. Kreipe, MD, Stefan Fruehauf, MD, Anthony D. Ho, MD

Blood (2011) 118 (21): 4514.

https://doi.org/10.1182/blood.V118.21.4514.4514

Published: 2011

Journal Articles

Gene Therapy of Chronic Myelogenous Leukemia Using Pseudotyped Recombinant Adeno-Associated Viral Vectors.

Leopold Sellner, MD, Marlon R Veldwijk, PhD, Jürgen A. Kleinschmidt, PhD, Stephanie Laufs, PhD, Julian Topaly, MD, W. Jens Zeller, MD, Frederik Wenz, MD, Stefan Fruehauf, MD

Blood (2009) 114 (22): 4506.

https://doi.org/10.1182/blood.V114.22.4506.4506

Published: 2009

Journal Articles

Efficient Gene Transfer into Human CD34 + Peripheral Blood Progenitor Cells Using Pseudotyped Recombinant Adeno-Associated Viral Vectors

Leopold Sellner, Marlon Veldwijk, PhD, Marius Stiefelhagen, Jurgen A. Kleinschmidt, PhD, Stephanie Laufs, PhD, Julian Topaly, MD, W. Jens Zeller, MD, Frederik Wenz, MD, Stefan Fruehauf, MD

Blood (2008) 112 (11): 4627.

https://doi.org/10.1182/blood.V112.11.4627.4627

Published: 2008

Journal Articles

The CXCR4-Antagonist AMD3100 Augments the Number of Mobilized Peripheral Blood Progenitor Cells (PBPC) When Added to a G-CSF Standard Mobilization Regime and AMD3100-Mobilized PBPC Result in Rapid Hematopoietic Reconstitution after Autologous Transplantation.

Stefan Fruehauf, MD, Timon Seeger, Julian Topaly, MD, Doris Herrmann, PhD, Falk Dillmann, Per Humpert, MD, Gary Calandra, MD, PhD, Stephanie Laufs, PhD, Hartmut Goldschmidt, MD, Anthony D. Ho, MD

Blood (2005) 106 (11): 1961.

https://doi.org/10.1182/blood.V106.11.1961.1961

Published: 2005

Journal Articles

Treatment of Imatinib-Sensitive and -Resistant Chronic Myelogenous Leukemia Cells with a Combination of Imatinib and Farnesyltransferase Inhibitors.

Aleksandar Radujkovic, Julian Topaly, MD, W. Jens Zeller, MD, Anthony D. Ho, MD, Stefan Fruehauf, MD

Blood (2005) 106 (11): 4881.

https://doi.org/10.1182/blood.V106.11.4881.4881

Published: 2005

Journal Articles

Combination Treatment with Imatinib and Mitoxantrone/Etoposide Is a Suitable Preparative Regimen before Allogeneic Transplantation in Patients with Myeloid Blast Crisis of Chronic Myeloid Leukemia.

Stefan Fruehauf, MD, Julian Topaly, MD, Eike C. Buss, MD, Tanja Lahaye, MD, Oliver G. Ottmann, MD, Thomas Fischer, MD, Bertold Emmerich, MD, Ulrike Haus, Rudiger Hehlmann, MD, Anthony D. Ho, MD, Andreas Hochhaus, MD

Blood (2005) 106 (11): 1105.

https://doi.org/10.1182/blood.V106.11.1105.1105

Published: 2005

Journal Articles

Highly Efficient Peripheral Blood Progenitor Cell Mobilization in Myeloma Patients by Single-Dose Application of 12 mg Pegylated G-CSF.

Stefan Fruehauf, MD, Timon Seeger, Julian Topaly, MD, Anthony D. Ho, MD, Hartmut Goldschmidt, MD

Blood (2005) 106 (11): 5264.

https://doi.org/10.1182/blood.V106.11.5264.5264

Published: 2005

Journal Articles

A Multicenter Phase I/II Trial of the Combination of Imatinib Mesylate with Mitoxantrone/Etoposide and Cytarabine in Patients with CML in Myeloid Blast Crisis: A Trend to a Longer Survival in Patients Receiving More Aggressive Treatment Schedules.

Stefan Fruehauf, MD, Julian Topaly, MD, Eike C. Buss, MD, Thomas Fischer, MD, Bertold Emmerich, MD, Harald Gschaidmeier, MD, Rudiger Hehlmann, MD, Andreas Hochhaus, MD

Blood (2004) 104 (11): 2929.

https://doi.org/10.1182/blood.V104.11.2929.2929

Published: 2004

Journal Articles

Synergism between 17-AAG and Imatinib in Imatinib-Resistant CML Cells: Inhibition of P-Glycoprotein by 17-AAG as a New Mechanism of Increasing Imatinib Activity.

Aleksandar Radujkovic, Moritz Schad, Julian Topaly, MD, Stephanie Laufs, PhD, Anna Jauch, MD, Beate Schultheis, MD, Junia V. Melo, MD, Anthony D. Ho, MD, Stefan Fruehauf, MD, W. Jens Zeller, MD

Blood (2004) 104 (11): 2094.

https://doi.org/10.1182/blood.V104.11.2094.2094

Published: 2004

NARROW

Treatment of Myelofibrosis Using I.V. Treosulfan and Autologous Peripheral Blood Progenitor Cell Transplantation Is Feasible and Results in Hematologic Responses – Long-Term Follow-up and Final Analysis of a One-Armed Clinical Study and of Individual Cases

Gene Therapy of Chronic Myelogenous Leukemia Using Pseudotyped Recombinant Adeno-Associated Viral Vectors.

Efficient Gene Transfer into Human CD34 + Peripheral Blood Progenitor Cells Using Pseudotyped Recombinant Adeno-Associated Viral Vectors

The CXCR4-Antagonist AMD3100 Augments the Number of Mobilized Peripheral Blood Progenitor Cells (PBPC) When Added to a G-CSF Standard Mobilization Regime and AMD3100-Mobilized PBPC Result in Rapid Hematopoietic Reconstitution after Autologous Transplantation.

Treatment of Imatinib-Sensitive and -Resistant Chronic Myelogenous Leukemia Cells with a Combination of Imatinib and Farnesyltransferase Inhibitors.

Combination Treatment with Imatinib and Mitoxantrone/Etoposide Is a Suitable Preparative Regimen before Allogeneic Transplantation in Patients with Myeloid Blast Crisis of Chronic Myeloid Leukemia.

Highly Efficient Peripheral Blood Progenitor Cell Mobilization in Myeloma Patients by Single-Dose Application of 12 mg Pegylated G-CSF.

A Multicenter Phase I/II Trial of the Combination of Imatinib Mesylate with Mitoxantrone/Etoposide and Cytarabine in Patients with CML in Myeloid Blast Crisis: A Trend to a Longer Survival in Patients Receiving More Aggressive Treatment Schedules.

Synergism between 17-AAG and Imatinib in Imatinib-Resistant CML Cells: Inhibition of P-Glycoprotein by 17-AAG as a New Mechanism of Increasing Imatinib Activity.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only